ISSN: 0213-005X

Indexed in:

Index Current Contents/Clinical Medicine, JCR, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, CANCERLIT, SCOPUS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

2.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.355

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.381

View more metrics

Journal Information

Back to article

Statistics

Follow this link to access the full text of the article

Original article

In vitro activity of ceftobiprole and dalbavancin against a collection of coagulase-negative staphylococci isolates from clinical samples with reduced susceptibility to daptomycin and/or resistant to linezolid or glycopeptides

Evaluación de la actividad in vitro de ceftobiprol y dalbavancina frente a estafilococos coagulasa negativos con sensibilidad disminuida a daptomicina y/o resistentes a linezolid o glucopéptidos aislados de muestras clínicas

Silvia Velasco de la Fuentea,

Corresponding author

silviavefu@gmail.com

Corresponding author.

, Marta Fernández-Martineza, Jesús Rodríguez Lozanoa, Daniel Pablo-Marcosa, María Sillera, Jorge Calvo Montesa,b

a Microbiology Service, University Hospital Marqués de Valdecilla – IDIVAL, Santander, Spain

b CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Spain

Read

342

Times
was read the article

Total PDF

250

Total HTML

Share statistics

Article information

ISSN: 0213005X
Original language: English

DOI:10.1016/j.eimc.2022.06.011

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	17	2	19
2024 October	22	7	29
2024 September	29	5	34
2024 August	29	4	33
2024 July	11	10	21
2024 June	15	3	18
2024 May	22	3	25
2024 April	2	0	2
2024 February	1	0	1
2024 January	2	0	2
2023 December	3	0	3
2023 November	97	37	134
2023 March	0	4	4
2023 January	0	3	3
2022 August	0	14	14

Show all

Follow this link to access the full text of the article

Publish in

Enfermedades Infecciosas y Microbiología Clínica

La Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica agradece la colaboración de:

SOCIOS PROTECTORES

SOCIOS PATROCINADORES

- Becton Dickinson S.A.U.
- Janssen-Cilag, S.A.
- Angelini Farmacéutica, S.A.
- Biomerieux España, S,A.U.
- Merck Sharp & Dohme de España, S.A.
- Hologic Iberia, S.L.U.
- Laboratorios Menarini S.A.
- Accelerate Diagnostics S.L.
- Abbott Laboratories, S.A.
- Cepheid Iberia S.L.U.
- Illumina Productos de España. S.L.U.
- DiaSorin Iberia, S.A.
- GlaxoSmithKline, S.A.
- Sysmex España S.L.

Enfermedades Infecciosas y Microbiología Clínica follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter